Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier FunctionPRNewsWire • 08/20/20
Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 08/10/20
Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common StockPRNewsWire • 08/05/20
Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common StockPRNewsWire • 08/03/20
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/03/20
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate UpdatePRNewsWire • 07/30/20
Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19PRNewsWire • 07/27/20
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19PRNewsWire • 06/15/20
